Elanco Animal Health (NYSE:ELAN) Updates Q2 2025 Earnings Guidance

Elanco Animal Health (NYSE:ELAN - Get Free Report) updated its second quarter 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 0.170-0.210 for the period, compared to the consensus earnings per share estimate of 0.200. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. William Blair upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday. Piper Sandler decreased their price target on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Finally, Stifel Nicolaus lifted their price target on Elanco Animal Health from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Monday, May 19th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.17.

Elanco Animal Health Stock Performance

ELAN stock traded up $0.02 during midday trading on Friday, reaching $14.32. The company had a trading volume of 5,611,213 shares, compared to its average volume of 5,104,818. The company has a quick ratio of 1.46, a current ratio of 2.71 and a debt-to-equity ratio of 0.68. The stock has a 50 day moving average price of $12.39 and a 200 day moving average price of $11.50. Elanco Animal Health has a fifty-two week low of $8.02 and a fifty-two week high of $15.78. The firm has a market capitalization of $7.11 billion, a PE ratio of 19.34, a P/E/G ratio of 2.80 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, beating analysts' consensus estimates of $0.31 by $0.06. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the previous year, the firm posted $0.34 earnings per share. Elanco Animal Health's quarterly revenue was down 1.0% compared to the same quarter last year. Analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current year.

Hedge Funds Weigh In On Elanco Animal Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Elanco Animal Health during the first quarter valued at approximately $2,065,000. Goldman Sachs Group Inc. raised its holdings in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock valued at $50,268,000 after buying an additional 2,445,872 shares during the last quarter. Empowered Funds LLC raised its holdings in shares of Elanco Animal Health by 35.2% during the first quarter. Empowered Funds LLC now owns 15,835 shares of the company's stock valued at $166,000 after buying an additional 4,121 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Elanco Animal Health by 4.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company's stock valued at $18,830,000 after buying an additional 76,408 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.